Key result
Monoclonal antibodies against EV71 3Dpol improve survival to ~39% in challenged neonatal mice.
Why the study?
Enterovirus A 71 can cause severe neurological and cardiopulmonary complications, but no vaccine or definitive antiviral drug is available.
Absolute Event Rate: 38.5% vs 0%
p-value: p=<0.01
Monoclonal antibodies against EV71 3Dpol inhibit viral replication in vitro and provide partial protection in a neonatal murine model, suggesting potential as therapeutic candidates.
These mAbs enable EV71 3D pol studies; leaves open antiviral efficacy and clinical translation.
Enterovirus A 71 (EV71) is a neurotropic virus that may lead to acute flaccid paralysis, encephalitis, cardiopulmonary failure or even death. No vaccine and defensive drug controlling EV71 is currently available, novel and efficient antiviral drug or vaccine is therefore urgently needed. 3D pol (RNA-dependent RNA polymerase (RdRp)) has been an important target for anti-EV71 drug development. A panel of monoclonal IgG antibodies (mAbs) against EV71 3D pol were generated by traditional cell fusion methods. And the antibody affinity and specificity to EV71 3D pol were evaluated by Enzyme-linked Immunosorbent Assay (ELISA), Indirect Fluorescent Assay (IFA) and Western blotting. Antiviral activities of these antibodies were also determined in vitro and in vivo. Two mAbs towards EV71 3D pol were able to effectively suppress EV71 replication in Vero-1008 cell when intracellarly delivered. And they also dampened the RNA polymerase activity of 3D pol in vitro. More importantly, these mAbs provided partial protection in EV71-challenged neonatal murine challenge model. These results showed that two of mAbs against EV71 3D pol inhibited EV71 replication and could be utilized as promising therapeutic drug candidate.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied Enterovirus A 71 (EV71) infection (n=54). Monoclonal antibodies against EV71 3Dpol (3A12 and 2A10) vs. Irrelevant mAb (5G10) or PBS was evaluated on Survival rate at 16 days post-challenge (p=<0.01). Monoclonal antibodies 3A12 and 2A10 against EV71 3Dpol significantly improved survival to 38.5% and 27.3%, respectively, compared to 0% in controls in EV71-challenged neonatal mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: